RecruitingNCT07263061

Time to Post-operative Recovery of Serum Albumin as a Predictor of Outcome in Major Hepato Pancreato Biliary Surgeries


Sponsor

Institute of Liver and Biliary Sciences, India

Enrollment

1,000 participants

Start Date

Dec 7, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Hepatobiliary and Pancreatic surgery is associated with substantial risk of postoperative complications. Albumin is a negative acute phase protein. Its rapid decline may be due to degree of inflammation due to surgical procedures. The decline may due to multifactorial causes. Currently, contemporary data regarding the time to recovery of albumin, as a marker for early recovery of patient from surgical stress is sparse. Delta albumin is influenced by perioperative fluid administration and albumin supplementation. Delta albumin may not reflect the true surgical stress. Early post op albumin is a reflection of intraoperative events and not postoperative recovery or events and is unpredictable. Shorter recovery time of albumin is associated with less post op complications and hospital stay. Earlier recovery of albumin predicts lower morbidity and shorter hospital stay.


Eligibility

Min Age: 13 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying NO TREATMENT for people with bile duct diseases, hepatobiliary disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 13 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNO TREATMENT

NO TREATMENT


Locations(1)

ILBS

New Delhi, National Capital Territory of Delhi, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07263061


Related Trials